Rituximab promotes long-term response for patients with immune destruction of platelets
A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP). In study results published online today in Blood, the Journal of the American Society of Hematology (ASH), investigators at Weill Cornell Medical College provide the very first long-term outcome data for patients with chronic ITP treated with rituxamab.
Approximately 200,000 Americans suffer from ITP, a bleeding disorder in which the immune system destroys blood cells called platelets that are necessary for normal blood clotting, which can result in excessive bleeding and heavy bruising.1 Common treatment options for increasing platelet counts in the majority of patients with ITP include corticosteroid drug therapy, used to suppress a patient's immune system in order to help bring platelet counts back to normal; splenectomy, the surgical removal of the spleen, to halt the destruction of antibody-coated platelets found in the organ; and newer thrombopoietin (TPO)-mimetic agents to help stimulate platelet production. While these treatments are successful in many patients, all are associated with side effects: corticosteroids are associated with bone loss, cataracts, and other serious toxicity with long-term use; splenectomy can increase a patient's risk of infection; and TPO-mimetic agents can result in blood clots, and their long-term response in patients is not well-studied. In addition to their reported side effects, some patients with ITP stop responding or have insufficient response to these therapies.
More than ten years ago, researchers identified rituximab as an alternative treatment for patients with chronic ITP who have failed at least one other therapy. Rituximab specifically destroys B-cells the cells responsible for producing antibodies that coat platelets and lead to their destruction with low toxicity and decreased risk of infection compared to other treatments. Previous studies have shown that rituximab treatment resulted in normalized platelet counts lasting longer than one year in some patients with chronic ITP. Despite these encouraging reports, long-term data were previously lacking, and the durability and long-term safety of this treatment were largely unknown.
"While rituximab therapy for chronic ITP has been an exciting development, until now, due to a lack of sufficient patient numbers and follow-up in previous studies, we have only known how this treatment will affect ITP patients in the short term," said Vivek L. Patel, PhD, the study's first author and Research Associate at Weill Cornell Medical College in New York. "By utilizing the longest follow-up and the largest number of responders to the drug, our study sought to determine how children and adults with chronic ITP treated with rituximab would fare three, four, and five years down the road."
In this follow-up study, Dr. Patel's team reviewed 18 published clinical trials assessing rituximab treatment in children and adults with ITP and calculated initial and one-year response rates for 138 patients treated in 2000-2007 from seven clinical centers in the United States and Europe. Seventy-two adults with ongoing response one year from first treatment and 66 children with partial or complete response of any duration were included in the long-term analysis. The investigators calculated five-year response rates of 26 percent for children and 21 percent for adults. The researchers also analyzed the relationship of other clinical variables in response to rituximab and found no difference in projected five-year outcomes in children and adults who had undergone prior splenectomy versus those who had not. Age, gender, prior ITP duration, and response to other ITP treatment were also not predictive of duration of response.
Results are particularly encouraging for ITP patients and their physicians who now have more substantial long-term data to help them decide whether and when to treat with rituximab. "The results from this study provide clinicians and patients with accurate and realistic expectations of the long-term effect of rituximab and its potential to become a first-line treatment for ITP," said James B. Bussel, MD, senior author and Professor of Pediatrics at Weill Cornell Medical College. "Our next step is to try to augment the effect of rituximab by combining it with dexamethasone, a common steroid therapy for ITP, in order to determine its effect in conjunction with known treatment strategies."
More information: 1About ITP. Platelet Disorder Support Association. www.pdsa.org/media… out-itp.html . Accessed April 30, 2012.
Provided by American Society of Hematology
- Study supports new, highly effective treatment for blood disorder Mar 20, 2009 | not rated yet | 0
- Romiplostim more effective than standard care for immune thrombocytopenia Nov 10, 2010 | not rated yet | 0
- Rituximab reduces kidney inflammation in patients with lupus Mar 04, 2009 | not rated yet | 0
- Rituximab and fludarabine produce long-term remissions in CLL Feb 25, 2011 | not rated yet | 0
- Immune responses to tetanus vaccine unchanged for RA patients on rituximab Jan 06, 2010 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Faraday's law on circular wire
17 minutes ago In my examples on Faraday's law in my book, they use a drawing of a magnet approaching a circular wire. The changing magnetic flux then induces an...
Specific Exergy vs Specific Flow Exergy
1 hour ago I'm having some difficulty understanding exactly what the difference between the definitions of these values are. As I understand it, in terms of...
The Durability of Bone: Long Falls
10 hours ago I am doing a paper on the physics in Valve's Portal and got interested in the "Long Fall Boots" that prevent any damage no matter how far you fall. I...
Is energy convertible to matter?
11 hours ago Can we convert energy to matter?
Rotating electron as a dipole is this right?
14 hours ago An electron as shown by the Stern Gerlach experiment behaves like a dipole (albeit only in one of two states). I have been trying to figure out how...
Dipole term in multipole expansion
18 hours ago Hi. I'm having some difficult in understanding something about the dipole term in a multipole expansion. Griffiths writes the expansion as a sum of...
- More from Physics Forums - Classical Physics
More news stories
Phthalates: Study links chemicals widely found in plastics, processed food to elevated blood pressure in children, teens
Plastic additives known as phthalates (pronounced THAL-ates) are odorless, colorless and just about everywhere: They turn up in flooring, plastic cups, beach balls, plastic wrap, intravenous tubing and—according to the ...
Pediatrics 3 hours ago | not rated yet | 1 |
A study by Alexandra L. C. Martiniuk, M.Sc, Ph.D., of The George Institute for Global Health, Sydney, Australia, and colleagues suggests less sleep per night is associated with a significant increase in the risk for motor ...
Pediatrics May 20, 2013 | not rated yet | 0
Whole-cell pertussis vaccines were more effective at protecting against pertussis than acellular pertussis vaccines during a large recent outbreak, according to a new Kaiser Permanente study published in Pediatrics.
Pediatrics May 20, 2013 | not rated yet | 0 |
Levels of physical inactivity and obesity are very high in children, with fewer than 50% of primary school-aged boys and fewer than 28% of girls meeting the minimum levels of physical activity required to maintain health. ...
Pediatrics May 17, 2013 | 5 / 5 (1) | 0
Poisonings in young children have increased over the past decade, mainly due to medications in the home. A new study led by the Central Ohio Poison Center at Nationwide Children's Hospital, found that medication-related poisonings ...
Pediatrics May 16, 2013 | not rated yet | 0
Italian lawmakers on Wednesday gave their final approval to a law that allows limited use of a controversial type of stem cell therapy which has been condemned by many scientists but has given hope to families of terminally-ill ...
38 minutes ago | not rated yet | 0
Beta-blockers, normally used for high blood pressure, could enhance the effectiveness of chemotherapies in treating neuroblastoma, a type of children's cancer, according to a new study published in the British Jo ...
8 minutes ago | not rated yet | 0
A Japanese cancer specialist said Wednesday she has started the world's first clinical trial of a powerful, non-surgical, short-term radiation therapy for breast cancer.
18 minutes ago | not rated yet | 0
(AP)—Alabama health officials say a mysterious respiratory illness has left five people hospitalized and two dead in the southeastern part of the state.
48 minutes ago | not rated yet | 0
New research at The University of Nottingham aimed at preventing harmful blood clots associated with heart disease and stroke has recently received a major funding boost from the British Heart Foundation.
23 minutes ago | not rated yet | 0
New mothers throughout Australia are needed to help QUT sleep researchers investigate whether the disrupted sleep experienced by mothers when caring for their new baby raises the risk of injury while driving.
16 minutes ago | not rated yet | 0